Biomarker Feedback to Motivate Cessation in Pregnancy

Pregnancy Clinical Trial

— MAW Phase 3  

Official title:

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) - Phase 3 Pilot Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02431611
• Other study ID #: 11-001144-02
• Status: Completed
• Phase: Phase 2
• First received: April 14, 2015
• Last updated: December 15, 2017
• Start date: March 2015
• Est. completion date: December 2017

Study information

• Verified date: December 2017
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 3 Pilot Clinical Trial.

Description:

Developing effective tobacco cessation interventions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobacco-related cancer health disparities. The proposed project builds on the investigators' successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. The investigators propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 the investigators will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, the investigators will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 60 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance the investigators' understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.

This is the third and final phase of the project.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Alaska Native

• 18 years or older

• provide written informed consent

• be currently pregnant and at <24 weeks gestation

• reside in Anchorage and plan to deliver at the ANMC

• current tobacco user defined as any use of Iqmik, commercial ST, and/or cigarettes during the past 7 days.

Exclusion Criteria:

• use of using nicotine replacement therapy or medications for tobacco cessation or participation in a behavioral cessation program within the past 30 days

• another woman from the same household has enrolled.

Related Conditions & MeSH terms

• Nicotine Dependence
• Pregnancy
• Tobacco Use Disorder

Intervention

Behavioral:
• Biomarker feedback (phone based smoking cessation counseling)
Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
• Control condition (phone based smoking cessation counseling)
phone-based behavioral smoking cessation counseling

Locations

Country	Name	City	State
United States	Alaska Native Tribal Health Consortium	Anchorage	Alaska

Sponsors (4)

Lead Sponsor	Collaborator
Mayo Clinic	Alaska Native Tribal Health Consortium, University of California, San Francisco, University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	smoking abstinence in late pregnancy (self-reported abstinence verified with cotinine)	self-reported abstinence verified with cotinine	at week 36 gestation or greater up to the time of delivery
Secondary	Self-efficacy (Self-reported confidence scale)	Self-reported confidence scale	at week 36 gestation or greater up to the time of delivery